Prospective replication study implicates the catechol-O-methyltransferase Val¹⁵⁸Met polymorphism as a biomarker for the response to morphine in patients with cancer.

ABSTRACT: Genetic differences in humans cause clinical difficulties in opioid treatment. Previous studies indicate that a single nucleotide polymorphism in the catechol-O-methyltransferase (COMT) gene (rs4680; p.Val¹⁵⁸Met) may present as a predictive biomarker for the response to morphine treatment. In our previous pilot exploratory study, patients with a G/G genotype were demonstrated to require a higher dose of morphine, compared with patients with A/A and A/G genotypes. In the present study, the aim was to replicate the findings in an independent cohort of opioid-treatment-naïve patients exhibiting various types of cancer. This prospective study was conducted from 2011 to 2012 at the Kindai University Faculty of Medicine. A total of 50 patients with opioid-treatment naïve and hi

SUBMITTER: Matsuoka H 

PROVIDER: S-EPMC5590034 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature